PetVet Magazine PetVet Magazine
  • Issues
  • Subscribe
  • Advisory Board
  • Media Kit
  • Advertise
PetVet Magazine
  • Issues
  • Categories
    • Client Services
    • Best Practices
    • Business Trends
    • Beyond the Stethoscope
    • Industry News
    • Lifestyle
    • Why It Matters To Me
    • PetVet Profile
    • PetVet Top 10
    • Veterinarian Life Advice
  • Subscribe
  • Advisory Board
  • Media Kit
  • Advertise
  • Business Trends

One Health: The Role of Fip in the Treatment of COVID-19

  • 2020-08-01
  • Steve Dale, CABC
Total
3
Shares
3
0
0
0

It’s not news that cats commonly get their own strain of coronavirus (FCoV). According to Niels Pedersen, PhD, DVM and distinguished professor at the University of California, Davis, in about ten percent of cats infected with the ubiquitous and otherwise benign FCoV, it transforms into an immune-mediated disease called feline infectious peritonitis (FIP). 

FIP had always been considered fatal until very recently. It turns out that treatment for FIP is nearly identical to Remdesivir, an anti-viral drug that President Donald Trump and U.S. Food and Drug Administration Commissioner Dr. Stephen Hahn have repeatedly mentioned, and is now approved for use to treat COVID-19. Remdesivir was created to treat Ebola by Gilead Sciences, but the results were mixed as other drugs proved better.

A few years back, Pedersen approached the non-profit funder of cat health studies, Winn Feline Foundation, as he sought to trial Remdesivir on cats with FIP. Winn’s scientific advisory board said, “Yes.” However, Gilead said, “Not so fast.” 

Pedersen says, “We chose to use GS-441424 for treatment of the coronavirus disease FIP because it had identical antiviral properties to Remdesivir, and at the time was not under consideration by Gilead Sciences for use in humans. GS-441424 is also much cheaper to make than Remdesivir. Therefore, there was no apparent conflict with using one form for cats and another form for humans.”

The initial trials even blew Pedersen away. GS-441424 worked to cure cats with effusive or wet FIP. However, Gilead had a change of heart and refused to grant animal rights for the drug. 

Back to the drawing board, Pedersen persevered. And with collaborators at Kansas State University, including Yunjeong Kim, PhD, DVM and associate professor in the department of pathobiology and diagnostics in the school’s College of Veterinary Medicine, they developed another nearly identical antiviral. This drug—known as GC376—also was trialled and had success in treating the wet form of FIP. Arguably, more success than the original Gilead drug. Currently, Anivive Lifescience is seeking FDA approval for this drug to treat cats with FIP, as announced at the Winn Feline Foundation symposium last November at U C Davis, Purrsuing FIP and Winning.   

Chinese companies realized the opportunity, as people are, of course, desperate to help their kitties with FIP—and these kitty parents aren’t waiting a year or longer for even a rushed FDA approval. So, Chinese manufacturers began to offer compounds on the black market (presumably like GC376 and also GS-441424, and therefore similar to Remdesivir—but they don’t disclose exactly what their compounds are). At least the leading Chinese company has anecdotally seen great success in treating cats with FIP around the world, but the cost isn’t inexpensive. And that company confirmed that they are working with the Chinese government regarding potential use of their compounds to treat COVID-19. Also, that company wants their drug approved here in the U.S. so they will no longer need to force cat owners to deal with the so-called black market.

In the meantime, Anivive, while waiting for GC376 to be approved for cats, is now seeking approval to trial the compound to treat COVID-19 in humans. The compound Anivive is seeking to approve in GC376 is incredibly similar to Remdesivir, except their mechanism of action is significantly different: GC376 is a protease inhibitor and Remdesivir is a polymerase inhibitor, explains Dr. David Bruyette, chief medical officer at Anivive. Bruyette adds that he believes the two drugs may work together in tandem far more effectively than either can alone. The notion is similar to providing a cocktail when it comes to treating HIV-AIDS, as one drug alone just doesn’t do the trick. 

Winn Feline Foundation president Dr. Drew Weigner says, “We hope that approved treatments for FIP will become available in the near future, and that greater efforts will be directed toward vaccination protocols, as this is the mainstay of controlling coronavirus infections in cats, and in all species.”

And no matter how all this plays out, veterinarians will no doubt be a part of this truly one health issue. +

Total
3
Shares
Share 3
Tweet 0
Share 0
Pin it 0
Steve Dale
Steve Dale, CABC

Steve Dale, CABC (Certified Animal Behavior Consultant) is the author of a popular blog, www.stevedalepetworld.com. He is the host of two national radio shows, and is heard on WGN Radio, Chicago. His many TV appearances include Oprah to National Geographic Explorer, and is a contributor on syndicated “HouseSmarts TV.” Steve edited “Decoding Your Dog,” authored by American College of Veterinary Behaviorists, and has contributed to many books and publications. Steve speaks around the world at animal behavior and veterinary conferences and serves on the Boards of the Winn Feline Foundation and Human Animal Bond Association. His many awards and honors include the AVMA Humane Award, and he was inducted into the Dog Writer’s Association Hall of Fame.

Next Article
  • Industry News

The Rise of Veterinary Specialties & What This Means for “the Vet”

  • 2020-08-01
  • Jenifer Chatfield, DVM, DACZM, DACVPM
View Post
Previous Article
  • Beyond the Stethoscope

Seeking Joy in the Journey: Five Tips to Eliminate Negative Thought Patterns

  • 2020-08-01
  • Angela Demaree, DVM, MPH, CHPC
View Post
  • December 2022 / January 2023
    • 2022-12-06
  • Veterinarian Life Advice
    • 2022-12-14
  • Answering the Age-Old Client Question: “What Should I Feed My Pet?”
    • 2022-12-14
  • Dr. Jonathan Stockman: Dedicated to Dispelling Myths & Revolutionizing Pet Nutrition
    • 2022-12-14
  • The Environmental Impact of Pet Food Protein Sources
    • 2022-12-14
  • 4 Plant-Based Dog Food Myths Debunked
    • 2022-12-14
  • Are You a Smarte? The Secret to Practice Success
    • 2022-12-14
  • 3 Nutrition Hacks to Help You Take Charge of Your Health
    • 2022-12-14
  • Veterinary Hope Foundation: Offering Support for the Animal Care Community
    • 2022-12-14
  • PetVet Top 10
    • 2022-12-14
  • October/November 2022 Issue
    • 2022-10-12
  • Veterinarian Life Advice
    • 2022-10-18
Social Accounts
  • Home
  • Subscribe
  • Advisory Board
  • Media Kit
  • Advertise
  • Privacy Policy
PetVet Magazine

A Practical Guide for Pet Health Professionals

Launching in the Summer of 2018, PetVet Magazine is an all-encompassing trade magazine that will cover all aspects of the ever changing veterinary industry. From customer service to the latest technology; PetVet Magazine will deliver Quality Content to Motivate & Educate Veterinarians and their staff.

© 2018-2022 PetVet Magazine

Issues
  • December 2022 / January 2023
  • October/November 2022 Issue
  • August/September 2022 Issue

Input your search keywords and press Enter.